Alyeska Investment Group
DALS

Alyeska Investment Group’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Alyeska Investment Group’s Portfolio DALS Stock Details DALS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500,000
Closed -$4.84M – 564
2022
Q2 		$4.84M Hold
500,000
– – 0.06% 296
2022
Q1 		$4.86M Hold
500,000
– – 0.05% 302
2021
Q4 		$4.91M Hold
500,000
– – 0.06% 284
2021
Q3 		$4.92M Buy
+500,000
New +$4.94M 0.06% 329

Other funds holding DALS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alyeska Investment Group's DALS Position: Q3 2022 in Review

Alyeska Investment Group sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2022, closing a stake of 500,000 shares — an estimated $4.84M sold.

Alyeska Investment Group first reported a position in DALS in Q3 2021 and held it in 4 quarters. The position peaked at $4.92M in Q3 2021. 43 funds tracked by Wall St. Rank hold DALS as of Q3 2022.

  • Alyeska Investment Group reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 500,000 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2022, an estimated $4.84M.
  • Alyeska Investment Group first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 4 quarters.
  • Alyeska Investment Group's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $4.92M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2022.

Based on Alyeska Investment Group's 13F filing for Q3 2022, filed 14 Nov 2022.